A Phase 3 interventional study of Basiliximab and Cyclosporine/cyclosporine microemulsion in Liver Transplantation and Infection, sponsored by Novartis. Completed at 1 site in Germany. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2011-09-22.
Sponsored by Novartis · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Systemic infection is still a major concern in young children with liver transplantation. The approach of this study is to reduce the risk of systemic infections by avoiding intraoperative steroids (another class of immunosuppressive drugs) given in combination with basiliximab, cyclosporine and steroids in pediatric de novo liver transplant recipients. The treatment is compared to the same treatment regimen including intraoperative steroids with respect to rejection episodes.
2,097 studies on the registry are indexed under Infections; 361 are open to participants now.
This study's enrollment of 77 is below the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was \<35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.
Drug: Basiliximab · Drug: Cyclosporine/cyclosporine microemulsion · Drug: Steroid
No intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was \<35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab and the first dose of steroids had to be administered within 8 hours after reperfusion of the graft and basiliximab was given as an intravenous bolus injection.
Drug: Basiliximab · Drug: Cyclosporine/cyclosporine microemulsion · Drug: Steroid
Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.
Also known as: Simulect®
Drug page: Cyclosporine
Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
Also known as: Sandimmun®/Sandimmun® Optoral
Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation
Graft loss is defined as being listed for a re-transplantation. The analysis was based on the locally performed biopsy assessments. Generally, patients not experiencing a relevant event (i.e., acute rejection, graft loss or death) were censored with the last visit date.
Time frame: 3 months after treatment
Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months
At biopsy of transplanted tissue sample, acute rejection has an onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever, and hypertension.
Time frame: 3 months
Number of Participants With Steroid Resistant Rejection Episodes Within Three and Six Months
To evaluate the efficacy of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the incidence of steroid resistant rejection episodes within three and six months.
Time frame: 3 and 6 months
Percentage of Participants Experiencing Death or Graft Loss Within Three and Six Months After Transplantation
Graft loss is defined as being listed for a re-transplantation.
Time frame: 3 months and 6 months
Number of Participants With Bacterial, Viral and Fungal Infections During Six Months
To evaluate the safety of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the episodes of bacterial, viral and fungal infections during six months.
Time frame: 6 months
Time of Onset of a First Biopsy Proven Acute Rejection
Biopsied Tissue shows rejection at onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever and hypertension .
Time frame: 6 months
Percentage of Participants With Treatment Failure Within Three and Six Months
To evaluate the proportion of patients with treatment failure treated with a therapy consisting of intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids within three and six months.
Time frame: 3 and 6 months
| Milestone | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| Started | 39 | 38 |
| Completed | 26 | 20 |
| Not completed | 13 | 18 |
| Withdrew: Adverse event | 1 | 8 |
| Withdrew: Lack of efficacy | 8 | 9 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Graft loss | 2 | 1 |
Graft loss is defined as being listed for a re-transplantation. The analysis was based on the locally performed biopsy assessments. Generally, patients not experiencing a relevant event (i.e., acute rejection, graft loss or death) were censored with the last visit date.
| Participants | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| Stratum age < 2 years (N=21, 24) | 8 | 15 |
| Stratum age 2-16 years (N=18, 14) | 14 | 11 |
| Total (N= 39, 38) | 22 | 26 |
At biopsy of transplanted tissue sample, acute rejection has an onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever, and hypertension.
| Participants | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months | 20 | 26 |
To evaluate the efficacy of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the incidence of steroid resistant rejection episodes within three and six months.
| Participants | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| Within 3 months post treatment | 2 | 2 |
| Within 6 months post treatment | 2 | 2 |
Graft loss is defined as being listed for a re-transplantation.
| Percentage of participants | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| Death within 3 months post treatment | 0.0 | 2.6 |
| Death within 6 months post treatment | 0.0 | 2.6 |
| Graft Loss within 3 months post treatment | 5.1 | 2.6 |
| Graft Loss within 6 months post treatment | 5.1 | 5.3 |
To evaluate the safety of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the episodes of bacterial, viral and fungal infections during six months.
| Participants | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| Fungal | 16 | 16 |
| Viral | 15 | 14 |
| Bacterial | 10 | 18 |
Biopsied Tissue shows rejection at onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever and hypertension .
| Months | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| Time of Onset of a First Biopsy Proven Acute Rejection | 1.93 (0.89 to NA) | 0.75 (0.49 to 1.31) |
To evaluate the proportion of patients with treatment failure treated with a therapy consisting of intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids within three and six months.
| Percentage of participants | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| 3 month: Age < 2 years (N= 21, 24) | 0.00 (0.00 to 16.11) | 4.17 (0.11 to 21.12) |
| 3 month: Age 2-16 years (N= 18, 14) | 11.11 (1.38 to 34.71) | 7.14 (0.18 to 33.87) |
| 3 Month: Total | 5.13 (0.63 to 17.32) | 5.26 (0.64 to 17.75) |
| 6 month: Age < 2 years (N= 21, 24) | 0.00 (0.00 to 16.11) | 4.17 (0.11 to 21.12) |
| 6 month: Age 2-16 years (N= 18, 14) | 11.11 (1.38 to 34.71) | 7.14 (0.18 to 33.87) |
| 6 Month: Total | 5.13 (0.63 to 17.32) | 5.26 (0.64 to 17.75) |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| With Intraoperative Steroids | — | 18/39 (46.2%) | 39/39 (100%) |
| Without Intraoperative Steroids | — | 23/38 (60.5%) | 38/38 (100%) |
| Event | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| Post procedural bile leakInjury, poisoning and procedural complications | 0/39 | 5/38 |
| Cytomegalovirus infectionInfections and infestations | 5/39 | 0/38 |
| GastroenteritisInfections and infestations | 2/39 | 3/38 |
| Complications of transplanted liverInjury, poisoning and procedural complications | 3/39 | 2/38 |
| Biliary dilatationHepatobiliary disorders | 0/39 | 2/38 |
| BilomaHepatobiliary disorders | 0/39 | 2/38 |
| CholangitisHepatobiliary disorders | 2/39 | 2/38 |
| Gastroenteritis norovirusInfections and infestations | 0/39 | 2/38 |
| Gastrointestinal anastomotic leakInjury, poisoning and procedural complications | 0/39 | 2/38 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/39 | 2/38 |
| Event | With Intraoperative Steroids | Without Intraoperative Steroids |
|---|---|---|
| HypertensionVascular disorders | 29/39 | 27/38 |
| PyrexiaGeneral disorders | 19/39 | 25/38 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 18/39 | 24/38 |
| HypomagnesaemiaMetabolism and nutrition disorders | 21/39 | 15/38 |
| FlatulenceGastrointestinal disorders | 20/39 | 16/38 |
| AnaemiaBlood and lymphatic system disorders | 17/39 | 17/38 |
| ConstipationGastrointestinal disorders | 15/39 | 17/38 |
| Antithrombin iii decreasedInvestigations | 16/39 | 16/38 |
| VomitingGastrointestinal disorders | 10/39 | 15/38 |
| HyperglycaemiaMetabolism and nutrition disorders | 8/39 | 15/38 |
| Age Continuous(years) | With Intraoperative Steroids | Without Intraoperative Steroids | Total |
|---|---|---|---|
| Mean | 3.08 ± 4.09 | 3.71 ± 5.36 | 3.39 ± 4.74 |
| Age, Customized(participants) | With Intraoperative Steroids | Without Intraoperative Steroids | Total |
|---|---|---|---|
| <2 years | 21 | 24 | 45 |
| from 2 to 16 years | 18 | 14 | 32 |
| Sex: Female, Male(Participants) | With Intraoperative Steroids | Without Intraoperative Steroids | Total |
|---|---|---|---|
| Female | 21 | 19 | 40 |
| Male | 18 | 19 | 37 |
The record gives a start of Mar 2004, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Basiliximab · Cyclosporine